Literature DB >> 18769310

Biodistribution and radiation dosimetry of [18F]F-PEB in nonhuman primates.

Marie-José Bélanger1, Stephen M Krause, Christine Ryan, Sandra Sanabria-Bohorquez, Wenping Li, Terence G Hamill, Hugh Donald Burns.   

Abstract

INTRODUCTION: The metabotropic glutamate receptor subtype 5 (mGluR5) is distributed throughout the central nervous system (CNS), and has been suggested to be a potential target for several CNS disorders suchas Parkinson's disease, pain, anxiety, depression, schizophrenia, and addiction. We report here on the rhesus monkey biodistribution and radiation dosimetry of [18F]3-fluoro-5-[(pyridine-3-yl)ethynyl]benzonitrile, [18F]F-PEB, a mGluR5 positron emission tomography (PET) radiotracer.
METHODS: Three male and two female rhesus monkeys were imaged using the Discovery ST PET/computed tomography scanner. A total of 25 whole body PET emissions were acquired over 3 h (23 emissions in one subject). Regions of interest were drawn in the brain, lungs, heart, liver, spleen, bladder, and testes. The absorbed radiation dose was calculated using OLINDA v1.
RESULTS: At the end of the imaging session, 45% of the [18F]F-PEB activity had been excreted by the liver and into the gastrointestinal tract and 10% had been excreted into the urinary bladder. When extrapolating to the adult human, the largest absorbed radiation doses were located in the upper large intestine (males: 0.18 mGy/MBq, females: 0.20 mGy/MBq) and small intestine (males: 0.16 mGy/MBq, females: 0.19 mGy/MBq). Effective radiation dose was 0.033 mSv/MBq for males and 0.034 mSv/MBq for females, similar to many other [18F] ligands.
CONCLUSION: The effective radiation dose of [18F]F-PEB obtained from rhesus is similar to many other clinically utilized [18F] ligands.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18769310     DOI: 10.1097/MNM.0b013e3283060c72

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  4 in total

1.  Kinetic analysis of the metabotropic glutamate subtype 5 tracer [(18)F]FPEB in bolus and bolus-plus-constant-infusion studies in humans.

Authors:  Jenna M Sullivan; Keunpoong Lim; David Labaree; Shu-Fei Lin; Timothy J McCarthy; John P Seibyl; Gilles Tamagnan; Yiyun Huang; Richard E Carson; Yu-Shin Ding; Evan D Morris
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-19       Impact factor: 6.200

Review 2.  Metabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging.

Authors:  Rajapillai L I Pillai; Dnyanesh N Tipre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-07       Impact factor: 9.236

3.  In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.

Authors:  Daniel J Rubins; Xiangjun Meng; Paul McQuade; Michael Klimas; Krista Getty; Shu-An Lin; Brett M Connolly; Stacey S O'Malley; Hyking Haley; Mona Purcell; Liza Gantert; Marie Holahan; Joel Lindgren; Pär Eklund; Caroline Ekblad; Fredrik Y Frejd; Eric D Hostetler; Dinko E González Trotter; Jeffrey L Evelhoch
Journal:  Mol Imaging Biol       Date:  2020-10-23       Impact factor: 3.488

4.  Production, biodistribution, and dosimetry of (47)Sc-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid as a bone-seeking radiopharmaceutical.

Authors:  Fatemeh Fathi; Leila Moghaddam-Banaem; Mojtaba Shamsaei; Ali Samani; Mohammad G Maragheh
Journal:  J Med Phys       Date:  2015 Jul-Sep
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.